Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tafenoquine + artesunate-pyronaridine
- Development stage
- Unknown
- Lead developer
- Menzies School of Health Research
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tafenoquine + artesunate-pyronaridine is a combination therapy being evaluated for the radical cure of *Plasmodium vivax* malaria. This regimen combines tafenoquine, a long-acting 8-aminoquinoline that targets dormant liver-stage parasites (hypnozoites) to prevent relapse, with artesunate-pyronaridine, an artemisinin-based combination therapy (ACT) that rapidly clears blood-stage parasites. The combination is specifically being studied in the TADORE-Plus Phase 4 clinical trial, conducted by the Menzies School of Health Research, to assess drug-drug interactions and clinical efficacy. This research aims to optimize radical cure strategies and potentially expand the use of tafenoquine beyond its current co-administration with chloroquine.
- Brand names
- KrintafelKozenisPyramax
- Other names
- tafenoquine plus artesunate-pyronaridineTADORE-Plus regimen
02
Targets
ATP2A (Sarcoplasmic reticulum Ca2+-ATPase)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on tafenoquine + artesunate-pyronaridine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tafenoquine + artesunate-pyronaridine.